Toripalimab, a humanized IgG4 monoclonal antibody against PD-1, is one of the first PD-1 inhibitors that were approved by the China Food and Drug Administration (CFDA) into clinical trials, which has demonstrated its manageable safety profile in several cancer types, such as urologic cancer and gastric cancer (10–12). This evidence concerns the gene PDCD1 and cancer.